Skip to main content

Advertisement

SpringerLink
Log in

Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication

  • Review Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent disease with a prolonged clinical course that most often involves the stomach. Clinically, for Helicobacter pylori-positive low-grade MALT lymphoma, antibiotics have been used as the first-line treatment. The recommended anti-Helicobacter triple drug therapy includes a proton pump inhibitor (or ranitidine bismuth citrate), clarithromycin, and amoxicillin (or metronidazole). Considering the difficulty involved with confirming histological remission and the lack of systemic endoscopic follow-up, much work remains to be done in this area. This review describes MALT lymphoma treatment methods and their efficacy, highlights results of the newest studies, and proposes avenues toward future developments in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338:1175–6.

    Article  PubMed  CAS  Google Scholar 

  2. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7.

    Article  PubMed  CAS  Google Scholar 

  3. Craig VJ, Cogliatti SB, Arnold I, et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia. 2010;24(6):1186–96.

    Article  PubMed  CAS  Google Scholar 

  4. Asenjo LM, Gisbert JP. Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review. Rev Esp Enferm Dig. 2007;99:398–404.

    Article  PubMed  CAS  Google Scholar 

  5. Boot H, de Jong D, van Heerde P, Taal B. Role of Helicobacter pylori eradication in high-grade MALT lymphoma. Lancet. 1995;346(8972):448–9.

    Article  PubMed  CAS  Google Scholar 

  6. Cavanna L, Pagani R, Seghini P, et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. World J Surg Oncol. 2008;6:35.

    Article  PubMed  Google Scholar 

  7. 2012 NCCN guideline NCCN lymphoma guideline version 2.2012. Available from: http://www.nccn.org.

  8. Caselli M, Zullo A, Maconi G, et al. “Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007;39:782–9.

    Article  PubMed  CAS  Google Scholar 

  9. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.

    Article  PubMed  CAS  Google Scholar 

  10. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–600.

    Article  PubMed  Google Scholar 

  11. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009;104:21–5.

    Article  PubMed  CAS  Google Scholar 

  12. Marshall B. Sequential therapy for Helicobacter pylori: a worthwhile effort for your patients. Ann Intern Med. 2008;148:962–3.

    Article  PubMed  Google Scholar 

  13. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet. 2007;370:1010–2.

    Article  PubMed  Google Scholar 

  14. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication. Gut. 2007;56:1353–7.

    Article  PubMed  CAS  Google Scholar 

  15. Jafri N, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148:1–10.

    Article  Google Scholar 

  16. Choi WH, Park DI, Oh SJ, et al. Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol. 2008;51:280–4.

    PubMed  Google Scholar 

  17. Zullo A, Hassan C, Andriani A, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009;104:1932–7.

    Article  PubMed  CAS  Google Scholar 

  18. Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23(31):8018–24.

    Article  PubMed  Google Scholar 

  19. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol. 2009;20(6):1086–93.

    Article  PubMed  CAS  Google Scholar 

  20. Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105–10.

    Article  PubMed  Google Scholar 

  21. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2011 [Epub ahead of print].

  22. Raderer M, Streubel B, Wohrer S, et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2006;55:616–8.

    Article  PubMed  CAS  Google Scholar 

  23. Nakamura S, Matsumoto T, Ye H, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer. 2006;107:2770–8.

    Article  PubMed  Google Scholar 

  24. Park HS, Kim YJ, Yang WI, et al. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol. 2010;16:2158–62.

    Article  PubMed  CAS  Google Scholar 

  25. Al Furaikh SS. Remission of high-grade B-cell lymphoma in a pediatric patient following Helicobacter pylori eradication. Pediatr Int. 2011;53:105–7.

    Article  PubMed  Google Scholar 

  26. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89:1350–5.

    Article  PubMed  CAS  Google Scholar 

  27. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet. 1995;345:1591–4.

    Article  PubMed  CAS  Google Scholar 

  28. Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97:1345–53.

    Article  PubMed  CAS  Google Scholar 

  29. Dong G, Liu C, Ye H, et al. BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. Int J Hematol. 2008;88(5):516–23.

    Article  PubMed  CAS  Google Scholar 

  30. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39–40.

    Article  PubMed  CAS  Google Scholar 

  31. Ferreri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol. 2007;63(1):65–71.

    Article  PubMed  Google Scholar 

  32. Owens SR, Smith LB. Molecular aspects of H. pylori-related malt lymphoma. Patholog Res Int. 2011;2011:1931–49.

    Google Scholar 

  33. Gisbert JP, Luna M, Gomez B, et al. Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. Aliment Pharmacol Ther. 2006;23:713–9.

    Article  PubMed  CAS  Google Scholar 

  34. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100:2083–99.

    Article  PubMed  Google Scholar 

  35. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut. 2007;56:1685–7.

    Article  PubMed  CAS  Google Scholar 

  36. Hong SS, Jung HY, Choi KD, et al. A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication. Helicobacter. 2006;11:569–73.

    Article  PubMed  Google Scholar 

  37. Morgner A, Schmelz R, Thiede C, et al. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol. 2007;13:3554–66.

    PubMed  CAS  Google Scholar 

  38. Suzuki H, Saito Y, Hibi T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. Gut Liver. 2009;3:81–7.

    Article  PubMed  CAS  Google Scholar 

  39. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815–24.

    Article  PubMed  Google Scholar 

  40. Son SH, Choi BO, Kim GW, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Int J Radiat Oncol Biol Phys. 2010;77(1):86–91.

    Article  PubMed  Google Scholar 

  41. Tomita N, Kodaira T, Tachibana H, et al. Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol. 2009;90(2):231–5.

    Article  PubMed  Google Scholar 

  42. Yamashita H, Nakagawa K, Asari T, et al. Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiother Oncol. 2008;87(3):412–7.

    Article  PubMed  Google Scholar 

  43. Gobbi PG, Corbella F, Valentino F, et al. Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. Ann Oncol. 2009;20(3):465–8.

    Article  PubMed  CAS  Google Scholar 

  44. Okada H, Takemoto M, Kawahara Y, et al. A prospective analysis of efficacy and long-term outcome of radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma. Digestion. 2012;86:179–86.

    Article  PubMed  CAS  Google Scholar 

  45. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13:2524–9.

    PubMed  CAS  Google Scholar 

  46. Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23:5061–6.

    Article  PubMed  Google Scholar 

  47. Lucas PC, Yonezumi M, Inohara N, et al. Bcl10 and MALT1, independent targets of chromosomal translocation in MALT-lymphoma, cooperate in a novel NF-ÎB signaling pathway. J Biol Chem. 2001;276:19012–9.

    Article  PubMed  CAS  Google Scholar 

  48. Kuo SH, Cheng AL, Lin CW, et al. t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. Cancer Chemother Pharmacol. 2011;68(6):1387–95.

    Article  PubMed  CAS  Google Scholar 

  49. Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2012 [Epub ahead of print].

  50. Jäger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20:3872–7.

    Article  PubMed  Google Scholar 

  51. Jager G, Neumeister P, Quehenberger F, et al. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol. 2006;17:1722–3.

    Article  PubMed  CAS  Google Scholar 

  52. Streubel B, Ye H, Du MQ, et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology. 2004;66:476–80.

    Article  PubMed  CAS  Google Scholar 

  53. Aviles A, Nambo MJ, Neri N, et al. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol. 2005;22:57–62.

    Article  PubMed  Google Scholar 

  54. Raderer M, Wohrer S, Bartsch R, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2005;23:8442–6.

    Article  PubMed  CAS  Google Scholar 

  55. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology. 2003;65:306–10.

    Article  PubMed  CAS  Google Scholar 

  56. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.

    Article  PubMed  CAS  Google Scholar 

  57. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979–83.

    Article  PubMed  CAS  Google Scholar 

  58. Levy M, Copie-Bergman C, Molinier-Frenkel V, et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma. 2010;51:284–90.

    Article  PubMed  CAS  Google Scholar 

  59. Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009;115:5210–7.

    Article  PubMed  CAS  Google Scholar 

  60. Troch M, Kiesewetter B, Dolak W, et al. Plasmacytic differentiation in MALT lymphomas following treatment with rituximab. Ann Hematol. 2012;91(5):723–8.

    Article  PubMed  CAS  Google Scholar 

  61. Troch M, Kiesewetter B, Willenbacher W, et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue-lymphoma: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2012 [Epub ahead of print].

  62. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–64.

    Article  PubMed  CAS  Google Scholar 

  63. Hoffmann M, Troch M, Eidherr H, et al. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma. 2011;52(1):42–5.

    Article  PubMed  CAS  Google Scholar 

  64. Ferrucci P, Vanazzi A, Crosta C, et al. Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin’s lymphoma. Ecancermedicalscience. 2008;2:79.

    PubMed  CAS  Google Scholar 

  65. Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol. 2005;23:7050–9.

    Article  PubMed  Google Scholar 

  66. Vrieling C, de Jong D, Boot H, et al. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008;87:405–11.

    Article  PubMed  Google Scholar 

  67. Zullo A, Hassan C, Andriani A, et al. Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis. Med Oncol. 2010;27(2):291–5.

    Article  PubMed  Google Scholar 

  68. Capelle LG, de Vries AC, Looman CW, et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008;44:2470–6.

    Article  PubMed  CAS  Google Scholar 

  69. Zucca E, Dreyling M, ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):113–4.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, People’s Republic of China

    Qing Guo, Shanqi Guo & Yizhuo Zhang

Authors
  1. Qing Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shanqi Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yizhuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yizhuo Zhang.

Additional information

Q. Guo and S. Guo contributed equally. They are joint first authors.

About this article

Cite this article

Guo, Q., Guo, S. & Zhang, Y. Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication. Int J Hematol 97, 735–742 (2013). https://doi.org/10.1007/s12185-013-1348-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1348-2

Keywords

Search

Navigation